Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: everolimus|DRUG: Placebo|DRUG: vinorelbine|DRUG: trastuzumab
Sponsor: Novartis Pharmaceuticals